GlobeNewsWire
15 Dec 2025, 12:05 UTC · 41w ago
Verdict
Headline takes no side. We score ZBIO +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 89% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Orelabrutinib met its primary endpoint in a Phase 2b study for Systemic Lupus Erythematosus (SLE), showing a statistically significant improvement in SRI-4 response rates.
More positive than 99% of claims this week
China's Center for Drug Evaluation (CDE) has approved the start of a Phase 3 registrational clinical trial for orelabrutinib in SLE.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 93% of claims this week
Zenas BioPharma holds exclusive rights to develop and commercialize orelabrutinib for non-oncology fields outside Greater China and Southeast Asia.
More positive than 87% of claims this week
A Phase 3 trial for orelabrutinib in Secondary Progressive MS (SPMS) is expected to initiate in the first quarter of 2026.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
Positive results from a Phase 2b study for orelabrutinib in SLE and strategic expansion of their product pipeline.
More positive than 89% of ticker scores this week
Achieved primary endpoint in Phase 2b trial for SLE and received approval for a Phase 3 trial in China.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
3h ago
−34.1%
Price is moving against the score
$26.76 vs $40.59 close before publication (Dec 12) · not market-adjusted
ZBIO chart →
